(Q34601527)

English

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

scientific article published on 9 December 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

0 references

1 reference

based on heuristic

inferred from title

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

L Klareskog

3

0 references

author name string

E C Keystone

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

M C Genovese

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

E C Hsia

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

S T Hall

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

P C Miranda

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

J Pazdur

7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

S-C Bae

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

W Palmer

9

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

J Zrubek

10

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

M Wiekowski

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

S Visvanathan

12

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Z Wu

13

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

M U Rahman

14

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

GO-FORWARD Study

15

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

0 references

publication date

9 December 2008

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

68

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

789-796

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674549

7 July 2018

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674549

7 July 2018

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674549

7 July 2018

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674549

7 July 2018

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674549

7 July 2018

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674549

7 July 2018

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674549

7 July 2018

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674549

7 July 2018

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674549

7 July 2018

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674549

7 July 2018

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674549

7 July 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674549

7 July 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674549

7 July 2018

Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674549

26 October 2018

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674549

26 October 2018

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674549

26 October 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674549

26 October 2018

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2674549

26 October 2018

Minimum important difference between patients with rheumatoid arthritis: the patient's perspective

1 reference

https://pubmed.ncbi.nlm.nih.gov/19066176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19066176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measurement of patient outcome in arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19066176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19066176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in favor

1 reference

https://pubmed.ncbi.nlm.nih.gov/19066176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://pubmed.ncbi.nlm.nih.gov/19066176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/19066176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ARD.2008.099010

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34601527&oldid=1556698791"